Brief: Guerbet: National Medical Products Administration Approves Lipiodol Ultra-Fluid in China
June 9 (Reuters) - GUERBET SA GRBT.PA :
* NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES
LIPIODOL®
ULTRA-FLUID FOR TRANS-ARTERIAL CHEMOEMBOLIZATION OF INTERMEDIATE
STAGE HEPATOCELLULAR CARCINOMA (HCC) IN ADULT PATIENTS IN CHINA
Source text: https://bit.ly/2Uq1CpM
Further company coverage: GRBT.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Guerbet SA
See all newsBrief: Guerbet Q1 Revenue At EUR 177.4 Mln
Guerbet Q1 revenue up 2.6% at CER on increased volumes in EMEA and Asia
Medical imaging firm Guerbet's 2025 revenue falls on lower sales activity in France
Brief: Guerbet Says FDA Approves Labeling Update For Guerbet's Elucirem Injection
France's Guerbet misses 2025 revenue estimates